J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Moltke, L.
Right arrow Articles by Shader, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Moltke, L.
Right arrow Articles by Shader, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Articles

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents

LL von Moltke, DJ Greenblatt, J Schmider, SX Duan, CE Wright, JS Harmatz, and RI Shader

Biotransformation of the imidazobenzodiazepine midazolam to its alpha-hydroxy and 4-hydroxy metabolites was studied in vitro using human liver microsomal preparations. Formation of alpha-hydroxy-midazolam was a high-affinity (Km = 3.3 mumol/L) Michaelis-Menten process coupled with substrate inhibition at high concentrations of midazolam. Formation of 4-hydroxy-midazolam had much lower apparent affinity (57 mumol/L), with minimal evidence of substrate inhibition. Based on comparison of Vmax/Km ratios for the two pathways, alpha-hydroxy-midazolam formation was estimated to account for 95% of net intrinsic clearance. Three azole antifungal agents were inhibitors of midazolam metabolism in vitro, with inhibition being largely consistent with a competitive mechanism. Mean competitive inhibition constants (Ki) versus alpha-hydroxy-midazolam formation were 0.0037 mumol/L for ketoconazole, 0.27 mumol/L for itraconazole, and 1.27 mumol/L for fluconazole. An in vitro-in vivo scaling model predicted inhibition of oral midazolam clearance due to coadministration of ketoconazole or itraconazole; the predicted inhibition was consistent with observed interactions in clinical pharmacokinetic studies. The selective serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine and its principal metabolite, norfluoxetine, also were inhibitors of both pathways of midazolam biotransformation, with norfluoxetine being a much more potent inhibitor than was fluoxetine itself. This finding is consistent with results of other in vitro studies and of clinical studies, indicating that fluoxetine, largely via its metabolite norfluoxetine, may impair clearance of P450-3A substrates.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
V. V. Hynninen, K. T. Olkkola, L. Bertilsson, K. J. Kurkinen, T. Korhonen, P. J. Neuvonen, and K. Laine
Voriconazole Increases while Itraconazole Decreases Plasma Meloxicam Concentrations
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 587 - 592.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Klieber, S. Hugla, R. Ngo, C. Arabeyre-Fabre, V. Meunier, F. Sadoun, O. Fedeli, M. Rival, M. Bourrie, F. Guillou, et al.
Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans
Drug Metab. Dispos., May 1, 2008; 36(5): 851 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. A. B. van Waterschoot, A. E. van Herwaarden, J. S. Lagas, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. A. Goldstein, D. C. Zeldin, J. H. Beijnen, and A. H. Schinkel
Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes
Mol. Pharmacol., March 1, 2008; 73(3): 1029 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ogasawara, T. Kume, and E. Kazama
Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys
Drug Metab. Dispos., March 1, 2007; 35(3): 410 - 418.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Farkas, L. E. Oleson, Y. Zhao, J. S. Harmatz, M. A. Zinny, M. H. Court, and D. J. Greenblatt
Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450-3A Activity: Comparison With Grapefruit Juice
J. Clin. Pharmacol., March 1, 2007; 47(3): 286 - 294.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Kirby, E. D. Kharasch, K. T. Thummel, V. S. Narang, C. J. Hoffer, and J. D. Unadkat
Simultaneous Measurement of In Vivo P-glycoprotein and Cytochrome P450 3A Activities.
J. Clin. Pharmacol., November 1, 2006; 46(11): 1313 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. He, M. H. Court, D. J. Greenblatt, and L. L. von Moltke
FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., July 1, 2006; 34(7): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. C. Day, C. G. Plopper, and M. V. Fanucchi
Age-specific pulmonary cytochrome P-450 3A1 expression in postnatal and adult rats
Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L75 - L83.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Isoherranen, K. L. Kunze, K. E. Allen, W. L. Nelson, and K. E. Thummel
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Drug Metab. Dispos., October 1, 2004; 32(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. C. Patki, L. L. von Moltke, J. S. Harmatz, L. M. Hesse, M. H. Court, and D. J. Greenblatt
Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 874 - 879.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y. W. F. Lam, C. L. Alfaro, L. Ereshefsky, and M. Miller
Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone
J. Clin. Pharmacol., November 1, 2003; 43(11): 1274 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-A. Kim and J.-Y. Park
INHIBITORY EFFECT OF GLYBURIDE ON HUMAN CYTOCHROME P450 ISOFORMS IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., September 1, 2003; 31(9): 1090 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt
IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5
Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Weaver, K. S. Graham, I. G. Beattie, and R. J. Riley
CYTOCHROME P450 INHIBITION USING RECOMBINANT PROTEINS AND MASS SPECTROMETRY/MULTIPLE REACTION MONITORING TECHNOLOGY IN A CASSETTE INCUBATION
Drug Metab. Dispos., July 1, 2003; 31(7): 955 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. H. Tran, L. L. von Moltke, K. Venkatakrishnan, B. W. Granda, M. A. Gibbs, R. S. Obach, J. S. Harmatz, and D. J. Greenblatt
Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors
Drug Metab. Dispos., December 1, 2002; 30(12): 1441 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kotegawa, B. E. Laurijssens, L. L. von Moltke, M. M. Cotreau, M. D. Perloff, K. Venkatakrishnan, J. S. Warrington, B. W. Granda, J. S. Harmatz, and D. J. Greenblatt
In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1228 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kuroha, A. Azumano, Y. Kuze, M. Shimoda, and E. Kokue
Effect of Multiple Dosing of Ketoconazole on Pharmacokinetics of Midazolam, a Cytochrome P-450 3A Substrate in Beagle Dogs
Drug Metab. Dispos., January 1, 2002; 30(1): 63 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Yu and R. L. Haining
Comparative Contribution to Dextromethorphan Metabolism by Cytochrome P450 Isoforms in Vitro: Can Dextromethorphan Be Used as a Dual Probe for Both CYP2D6 and CYP3A Activities?
Drug Metab. Dispos., November 1, 2001; 29(11): 1514 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Yamano, K. Yamamoto, M. Katashima, H. Kotaki, S. Takedomi, H. Matsuo, H. Ohtani, Y. Sawada, and T. Iga
Prediction of Midazolam{---}cyp3a Inhibitors Interaction in the Human Liver from in Vivo/in Vitro Absorption, Distribution, and Metabolism Data
Drug Metab. Dispos., April 1, 2001; 29(4): 443 - 452.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
I. Kawahara, Y. Kato, H. Suzuki, M. Achira, K. Ito, C. L. Crespi, and Y. Sugiyama
Selective Inhibition of Human Cytochrome P450 3A4 by N-[2(R)-Hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by Valspodar in Gene Transfectant Systems
Drug Metab. Dispos., October 1, 2000; 28(10): 1238 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Tang, M. Shou, Q. Mei, T. H. Rushmore, and A. D. Rodrigues
Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 453 - 459.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. S. Warrington, J. W. Poku, L. L. von Moltke, R. I. Shader, J. S. Harmatz, and D. J. Greenblatt
Effects of Age on In Vitro Midazolam Biotransformation in Male CD-1 Mouse Liver Microsomes
J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1024 - 1031.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. D. Perloff, L. L. von Moltke, M. H. Court, T. Kotegawa, R. I. Shader, and D. J. Greenblatt
Midazolam and Triazolam Biotransformation in Mouse and Human Liver Microsomes: Relative Contribution of CYP3A and CYP2C Isoforms
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 618 - 628.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
M. A. Gibbs, K. L. Kunze, W. N. Howald, and K. E. Thummel
Effect of Inhibitor Depletion on Inhibitory Potency: Tight Binding Inhibition of CYP3A by Clotrimazole
Drug Metab. Dispos., May 1, 1999; 27(5): 596 - 599.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Prueksaritanont, L. M. Gorham, B. Ma, L. Liu, X. Yu, J. J. Zhao, D. E. Slaughter, B. H. Arison, and K. P. Vyas
In Vitro Metabolism of Simvastatin in Humans [sbt]Identification of metabolizing enzymes and effect of the drug on hepatic P450s
Drug Metab. Dispos., October 1, 1997; 25(10): 1191 - 1199.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Clinical Pharmacology